1-6 of 6
Petra Klappers
Close
Sort by
Journal Articles

Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate and Prolongs Overall Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Max S. Topp, Nicola Goekbuget, MD, Gerhard Zugmaier, Andreas Viardot, MD, Matthias Stelljes, MD, Svenja Neumann, Heinz A. Horst, Albrecht Reichle, Reinhard Marks, Christoph Faul, MD, Monika Brueggemann, Matthias Ritgen, Petra Klappers, Noemi Mergen, Marie-Elisabeth Goebeler, Hermann Einsele, Ralf Bargou
Journal: Blood
Blood (2012) 120 (21): 670.
https://doi.org/10.1182/blood.V120.21.670.670
Published: 2012
Journal Articles

Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial

Max S. Topp, MD, Nicola Goekbuget, MD, Gerhard Zugmaier, MD, Andreas Viardot, MD, Matthias Stelljes, Svenja Neumann, MD, Heinz A. Horst, MD, Albrecht Reichle, MD, Reinhard E Marks, MD, Monika Brueggemann, MD, Matthias Ritgen, MD, Petra Klappers, Noemi Mergen, MD, Marie-Elisabeth Goebeler, MD, Hermann Einsele, Dieter Hoelzer, MD, Ralf Bargou, MD
Journal: Blood
Blood (2011) 118 (21): 252.
https://doi.org/10.1182/blood.V118.21.252.252
Published: 2011
Journal Articles

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m 2 /d Is Tolerable and Highly Effective

Andreas Viardot, MD, Mariele Goebeler, MD, Jurgen S. Scheele, MD, PhD, Gerhard Zugmaier, MD, Richard Noppeney, MD, Stefan Knop, MD, Max S Topp, MD, Dirk Nagorsen, MD, Matthias Klinger, PhD, Margit Schmidt, PhD, Petra Klappers, Peter Kufer, MD, Hermann Einsele, MD, Ralf Bargou, MD
Journal: Blood
Blood (2010) 116 (21): 2880.
https://doi.org/10.1182/blood.V116.21.2880.2880
Published: 2010
Journal Articles

Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.

Dirk Nagorsen, Gerhard Zugmaier, Peter Kufer, Matthias Klinger, Andreas Viardot, Mariele Goebeler, Margit Schmidt, Petra Klappers, Andreas Wolf, Christian Brandl, Patrick A Baeuerle, Ralf C Bargou
Journal: Blood
Blood (2009) 114 (22): 4798.
https://doi.org/10.1182/blood.V114.22.4798.4798
Published: 2009
Journal Articles

Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 μg/m 2 /d of BiTE® Antibody Blinatumomab.

Dirk Nagorsen, Gerhard Zugmaier, Andreas Viardot, Mariele Goebeler, Richard Noppeney, Margit Schmidt, Petra Klappers, Patrick A Baeuerle, Peter Kufer, Ralf C Bargou
Journal: Blood
Blood (2009) 114 (22): 2723.
https://doi.org/10.1182/blood.V114.22.2723.2723
Published: 2009
Journal Articles

Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL

Ralf C Bargou, MD, Peter Kufer, MD, Mariele Goebeler, MD, Stefan Knop, MD, Hermann Einsele, MD, Richard Noppeney, MD, Andreas Viardot, MD, Patrick A Baeuerle, PhD, Carsten Reinhardt, MD, Margit Schmidt, PhD, Petra Klappers, Dirk Nagorsen, MD, Gerhard Zugmaier, MD
Journal: Blood
Blood (2008) 112 (11): 267.
https://doi.org/10.1182/blood.V112.11.267.267
Published: 2008